Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
about
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells.Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Effects of modified FOLFOX-6 chemotherapy on cellular immune function in patients with gastric cancer.Perspectives on the clinical development of immunotherapy in prostate cancer.Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors.Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects.Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future OptionsCurrent landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitorsMonitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular CarcinomaDNA repair defects and implications for immunotherapyThe mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancerEmerging role of precision medicine in biliary tract cancersThe Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung CancerThe DNA damage response in immunotherapy and radiationTumor mutational burden is a determinant of immune-mediated survival in breast cancerBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitorsQ58736062Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing ApproachesTumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and deathComparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trialsCirculating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer
P2860
Q47120629-F38ECD91-2E5C-4EEE-83C9-16FDA05475F0Q47624848-6E29F7AD-39CE-40B4-BBFF-BE71148A49A0Q47666620-73783F9F-745B-41DB-BFEC-876946AA3DE3Q48620065-6C8EF53A-7E0A-4724-81A8-A5670531FB14Q49501422-6499A870-B2E1-40D8-98FB-B814C5F71C31Q52587406-5EA4701F-02A0-4437-BE77-0B635176EB4DQ52733765-1C79DFF6-ED14-4F99-ABD8-AF5501418182Q52743918-DB356A1A-1014-49C6-B639-B7B727210B4BQ55008531-7CFD2007-3668-4BD0-80DF-51203B2A9E20Q55019724-C379EA50-163C-4D3D-8641-1890E90C2566Q55029444-DEEEE614-08E3-4EB0-93B3-65A80203B21FQ55034685-6597D004-A95A-40DB-B3CD-F2022186CC5DQ55209598-F54E9AD9-41A7-4E5A-B8F1-27AF2E96A078Q55223567-176C5A3C-3016-462C-B4AD-971B0D687B55Q55318335-2FDE0037-0B72-4AB5-8DC5-B5DD5876EB6CQ55362111-36398022-26D2-4EF4-BF19-92546A218918Q55378109-5FD1E70F-0DB9-49CD-B303-CD76A8C0BEB4Q55413334-A132906D-63F1-4552-BCDE-D74FEF0AB515Q55418935-58DA5E13-5B3A-48C6-9A38-FA63F1381A69Q55515330-0C380D7F-494C-46C6-A857-928CBC61B492Q56890107-DC97939E-853D-420F-913F-2ECC4267F720Q56890243-FF631E91-CA74-4149-8353-302FBB0E39BEQ56891008-733F0D79-3A6E-47C7-8590-6D694BAA2545Q57057014-68B3C13F-6ADF-4CC7-8FE6-AC5BCB6AFF80Q57174763-AF129CC1-5540-4655-A4E5-1D4C84D1ADBBQ57298169-72AE4986-6A25-4B8F-9419-01237D143B4BQ57300289-575D4EE3-9556-434F-BDE9-ABA853FE5C21Q58119182-D197D0DB-BEDF-4C6A-B80D-C520A1ED493DQ58567735-B13F8940-6F6B-41DE-98E0-C577E619FC71Q58713932-8C84BFE3-41F0-4DFA-992A-72167D3718E6Q58736062-C29953EB-97E6-497D-8358-2B954CD05BF6Q58739937-394023B0-9FEE-42DA-87E7-4D9320E6AD47Q58764394-3C99B9B9-69B1-43BB-A0AD-77BA8F9CE3BAQ58768522-787F8732-AA58-4CA1-B7E1-78CE8F2AE97EQ58801896-81ABB67A-1742-4926-A7B9-90A5FDE01081
P2860
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Tumor Mutational Burden as an ...... unotherapy in Diverse Cancers.
@en
type
label
Tumor Mutational Burden as an ...... unotherapy in Diverse Cancers.
@en
prefLabel
Tumor Mutational Burden as an ...... unotherapy in Diverse Cancers.
@en
P2093
P2860
P1476
Tumor Mutational Burden as an ...... unotherapy in Diverse Cancers.
@en
P2093
Aaron M Goodman
Garrett M Frampton
Gregory A Daniels
Lyudmila Bazhenova
Philip J Stephens
Sandip P Patel
Shumei Kato
Vincent Miller
P2860
P356
10.1158/1535-7163.MCT-17-0386
P577
2017-08-23T00:00:00Z